AccuRXy
2027 Fundraise
AccuRxy
Safe Practice

One software platform for pharmacy education and pharmacy governance

AccuRXy is a subscription software business sold on one platform: Educate for pharmacy education and Regulate for medication-incident reporting and pharmacy governance. We start in Ireland and the UK, and the same engine carries us into new markets.

€900k

Seed round

Indicative, to be refined by the costed roadmap

2 products

Educate and Regulate

Distinct buyers, shared product team

7 countries

Feasibility interviews

Educators, deans and pharmacy operators

The problem02 / 29

Medication harm is costly and preventable, yet training and governance remain manual

$42bn

Estimated annual global cost of medication errors

WHO, Medication Without Harm

50%

WHO goal: cut severe avoidable medication harm

Third Global Patient Safety Challenge

2,000

Registered pharmacies in Ireland

PSI, year-end 2025

For educators

  • Writing, reviewing and maintaining clinically credible scenarios takes significant staff time
  • Students ask for more practice than faculty can build by hand
  • The established free tool, MyDispense, sets a low price anchor

For pharmacies

  • Regulators advise that all staff are trained to identify, manage and record errors and near misses
  • Reporting, follow-up actions, SOPs and training records sit in separate paper and spreadsheet systems
  • Owners and superintendents need clear oversight and retrievable evidence for inspection
Why now03 / 29

Simulation is growing fast, pharmacy is going digital, and AI makes content creation practical

Global medical simulation market (USD bn)

20262031

MarketsandMarkets projects a 15.3% CAGR, 2026 to 2031. Towards Healthcare independently estimates $3.05bn in 2024 rising to $12.94bn by 2034 (15.5% CAGR). Estimates vary by definition; this is the broader medical simulation market, not pharmacy alone.

  • Regulators increasingly allow specified pharmacy records, including controlled-drug registers, to be held electronically where software meets required standards
  • Expanding community-pharmacy clinical services create new consultation, governance and training-record needs
  • Simulation is established in health professions education; a 2023 ACCP review found positive effects on learner satisfaction, knowledge and skills, while noting more pharmacy-specific outcome studies are needed
  • Generative AI can draft scenarios and feedback quickly, with educator review and approval kept in the loop
Our solution04 / 29

Two products on one platform, from the classroom to the pharmacy counter

For schools of pharmacy

Educate

AI-assisted creation of medication-safety scenarios, linked questions and explanatory feedback, with educator review and approval before anything reaches a student.

For pharmacies and groups

Regulate

Medication incident and near-miss reporting, investigation, corrective actions, SOPs, inspection readiness and staff development in one connected workflow.

To be precise about scope: Regulate is a reporting and governance system. It does not perform real-time medication-error detection or live prescription checking. A future link between Regulate insights and Educate content could support incident-informed learning, using de-identified or synthetic material.

Product05 / 29

Educate: less preparation time for educators, more practice for students

Educators

  • AI Content Studio to generate, edit, review, publish and version scenarios
  • Curriculum alignment by topic, year level and competency area
  • Cohorts, assignments with due dates, attempt limits and feedback release
  • Class and student analytics with CSV and PDF export
  • Evidence Pack traceability showing the source material behind each generation stage

Students

  • Immersive scenario player with prescriptions, patient profiles and step-by-step decisions
  • Open practice mode for self-paced, ungraded learning
  • Optional VR pharmacy mode with queues and distractions
  • AI tutor, case study library and personal progress tracking
  • Points, levels, badges and a cohort leaderboard
Product06 / 29

Regulate: one workflow from near miss to corrective action to inspection evidence

Incident and safety

Structured error and near-miss reports, case management with audit trail, root cause analysis, action plans with owners and deadlines, Good Catches, safety alerts and a LASA database.

Governance and compliance

Regulator self-assessment and inspection readiness, CQI meetings, compliance checklists, SOP manager with staff acknowledgement, practice circulars and an inspection evidence export.

Clinical services and learning

Clinical-service records and training tracker, medicines disposal, controlled-drug workflows, training resources, certificates, CPD nudges and ePortfolio drafting.

Five role-based views (staff reporter, superintendent, manager, safety officer, administrator), multi-site organisations, anonymised benchmarking with consent, and AI-assisted capture from free text or photographs, always with human confirmation.

Product in action07 / 29

Working product screens from the current build

AccuRXy Educate · Scenario

Patient at counter

Margaret Doyle, 68

Community pharmacy · Dublin

Year 3

Prescription

Metformin 500 mg tablets

Two tablets twice daily with meals · 56 tablets

What is your first action?

Check the dose against the clinical record
Dispense as prescribed
Ask the patient about adherence
AccuRXy Regulate · Incident record

Incident record

Near miss at dispensing

Under review

Type

Dispensing error

Severity

No harm

Contributing factors

Look-alike packagingInterrupted workflowSimilar strengths
Assigned to · Quality leadFollow-up due 12 Nov

Illustrative interface views. On-screen figures are examples, not trial outcome measures.

Founders and team08 / 29

Three founders spanning pharmacy education, medication safety and commercial scale-up

Dr Cathal Cadogan

Dr Cathal Cadogan

Co-founder · Pharmacy education

Pharmacist and Associate Professor in Practice of Pharmacy at Trinity College Dublin, with expertise in pharmacy education and medicines optimisation.

Professor Cristín Ryan

Professor Cristín Ryan

Co-founder · Medication safety

Pharmacist and Professor in Practice of Pharmacy at Trinity College Dublin, with expertise in medication safety, professional development and quality improvement.

Andy O’Donoghue

Andy O’Donoghue

Co-founder · Commercial and technology

Digital health entrepreneur with commercial and technical expertise and a track record of building digitally disruptive businesses from start-up to acquisition.

Technical team

Dr Ian O’Keeffe · Dr Haider Khalid · Dr Saravanabalagi Ramachandran · Birva Mehta · Luciana Medeiros · Greg Carey

Partners and funding

Developed with the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin and the Learnovate Centre, supported by an Enterprise Ireland Commercialisation Fund Award.

Competition09 / 29

We compete on workflow, educator control and total customer value

PlayerSegmentWhat they offerOur angle
MyDispense (Monash)EducationFree pharmacy simulation with exercise authoring and assessmentFaster authoring and review workflow, curriculum fit, AI-assisted feedback. Must prove value over a free tool.
EHR GoEducationPharmacy platform with editable cases, OSCE and simulation. US$128 annual list, usually paid by studentsPriced below at €89 / US$89 for trial testing, with free faculty access as a possible message
Think Research (Pharmapod)PharmacyIncident case management, analytics, CQI, self-assessment and SOP management. Now part of a Canadian group, so our home markets are secondary to themRegulator-aligned workflow and content with local support, bringing reporting, actions, clinical-service records and staff learning together in one system
AccuRXyBothEducate and Regulate on one platform, with human approval and source traceabilityEducation-to-practice link as the product matures

Competitor descriptions reflect published offers checked 30 September 2026. Demonstrations and customer conversations will test practical fit before any price comparison is made public.

Academic market10 / 29

One price of €89: 55 schools is €1.96m a year, the full global base is €53m

600,000

Global planning base

IPSF represents 600,000+ pharmacy students and recent graduates

22,000

Initial reachable scenario

55 schools averaging 400 students, about 3.7% of the base

Ireland + UK

Initial sales focus

Plus accessible international relationships

Schools won (400 students each)LearnersAnnual revenue at €89
10 schools4,000€356k
25 schools10,000€890k
55 schools, initial scenario22,000€1.96m
Global base, full participation600,000€53m

€89 per student per year, held flat: growth comes from schools won, not price rises. Every 10 schools adds about €356k of annual recurring revenue; technician learners are not included.

Educate pricing11 / 29

€89 per student at launch, with €70 as the tested floor and €94 by Year 4 if CPI indexed

Annual price per student (US$)

EHR Go listEHR Go at 400AccuRXy US

US$89 is about 30% below EHR Go's US$128 list price and 25% below its 400-licence price. EHR Go usually charges students directly, so it is not proof of a school's budget.

  • €89 is the launch price to test, with €70 as the downside floor
  • Launch test: €89 in Europe and US$89 in America (separate local prices; the US price yields about 10.8% less per licence at current exchange rates)
  • Possible message: faculty access is free, students pay
  • What students already pay for one study tool: EHR Go US$128, Osmosis US$249, UWorld NAPLEX QBank from US$299, the RxPrep course US$999. €89 sits below that €115 to €275 band
  • These are US list prices paid by students directly, so they show what a student will spend, not what a European faculty budget holds
  • Willingness to pay at €89 is the key trial question, not a settled assumption
Regulate market and pricing12 / 29

€3,000 per site per year as a working price

€6.0m

Home-market annual ceiling

2,000 pharmacies at full adoption, €3,000 per site per year

€3,000

Working price per site per year

€250 per month, per site

€150,000

ARR from 50 paying sites

At €3,000 per site per year. That is 2.5% of the home market's 2,000 pharmacies.

  • Annual site subscription with group management and volume terms; implementation fees and optional modules priced separately
  • Three buyer shapes: a single community pharmacy at the working price; a buying group or professional association contracting for a whole membership; a large online or mail-order operator contracting at group level
  • A group agreement still prices per site but on volume terms, so a 200-site deal is a different negotiation from a single site
  • Buyers: owners, superintendent pharmacists and group leadership; users: managers, safety officers and staff; workflow fit and existing contracts decide the sale
  • Licensed community pharmacies in reach: c. 160,000 across the EU (PGEU), 10,152 in Canada (NAPRA, January 2026) and c. 19,000 independent pharmacies in the US (NCPA), c. 2,000 in Ireland
  • At €3,000 a site, the EU's 160,000 community pharmacies are about €480m of annual software value, and Ireland's 2,000 sites about €6m
Revenue scenarios13 / 29

ARR at illustrative scale

Educate at €89, 400 students per school

3 schools (1,200 students)€107k
5 schools (2,000 students)€178k
9 schools (3,600 students)€320k

Each bar is a school count, not a range: 3 schools is €107k, 5 is €178k, 9 is €320k. The 55 school ceiling of €1.96m is on the market slide.

Regulate at €3,000 per site per year

50 sites€150k
500 sites€1500k
2,000 sites€6000k

Single price, no ranges: €150k at 50 sites, €1.5m at 500 and €6.0m at 2,000.

Annualised subscription revenue is the value of a full year of contracted service, which differs from revenue recognised or cash collected in a partial year. Manufacturer-funded education is excluded until a funded use case exists.

Interactive model14 / 29

Model price and user counts

Growth path
Growth comes from school and site counts; price holds near list

Educate

Per student, per year

€/ yr

600 licences · €53k a year

Regulate

Per pharmacy site, per year

€/ yr

Deck working price €3,000, inside a €100 to €300 monthly range

Ireland has about 2,000 pharmacies in total

10 sites · €30k a year

Combined annual recurring revenue€83kYear 1
Educate 64% · €53kRegulate 36% · €30k

Illustrative only: full-year subscription value at list price, before discounts, VAT and implementation fees. Educate assumes one licence per student; Regulate prices a site, not a user.

Year 1 starts on the home-market pilot base: two pharmacy schools and ten sites. Year 3 adds UK schools and groups; by Year 4 Educate covers sixteen schools and Regulate about 500 sites, roughly one in four of Ireland's 1,912 community pharmacies once UK groups are included.

Why it scales15 / 29

Software economics: one platform, repeatable sales, revenue that compounds

One codebase, many markets

The generation engine, review workflow and evidence layer are shared. Regulatory content sits apart from the software, so a new jurisdiction is a content and compliance task rather than a rebuild.

Content compounds

Every approved scenario, question set and feedback explanation is reused across cohorts and customers, so each additional school adds margin instead of build cost.

Two buyers on one platform

Educate sells seats to schools at €89 per student per year; Regulate sells sites to pharmacies at €3,000 per site per year. Both draw on the same generation, review and evidence services.

Land, then expand

A school starts with one programme and adds year levels; a group starts with a handful of sites and adds the rest under group terms. Expansion happens inside accounts we already hold.

Both products are licence-based, so revenue follows the number of students and sites served rather than delivery hours.

Go-to-market16 / 29

Trials first, then paid contracts

Educate

  • Five priority institutions, engaging academic champions and budget holders together
  • Target: 3 to 5 institutions expressing intent to pay by August 2027
  • Sales case built on measured preparation time, quality and repeat use
  • Expect 3 to 6 month university compliance checks; Canada flagged as a more agile decision environment

Regulate

  • 3 to 5 buyer conversations by late January 2027; Cara is an active prospect
  • Pilot ambition: 2 to 3 organisations and 3 to 5 sites
  • At least one documented buying decision by M12 and first paid conversion by M15
  • Independent pharmacies and multi-site groups, with pricing refined through use

Pipeline goal: 15 to 20 qualified opportunities across both products by M15, each with a named buyer or champion and an agreed next action. A 5 to 6 member customer advisory board will meet quarterly. One practical partnership (education, distribution or integration) is prioritised; named candidates include Elsevier, Medscape, AMBOSS and Wolters Kluwer.

International expansion17 / 29

Ireland and the UK to first revenue, English-speaking schools next, Europe through partners

Now to mid 2027

Ireland and the UK

Home markets. Trials with Trinity, RCSI and Queen's Belfast, then first paid Educate contracts and Regulate pilots. PSI and GPhC aligned content is written once and reused.

Mid 2027 to 2028

Canada and Australia

English-language expansion where interest is already recorded: Toronto and UNSW, with Canada reading as the faster decision environment. Same product, local regulator and curriculum content pack.

2028 to 2029

Netherlands, Belgium, Portugal

Entered through a university or distribution partner rather than a direct sales hire, with translation funded by the partner or the account.

MarketEvidence already in handEntry routeTiming
IrelandHome institution and pre-pilot group; PSI content and terminologyDirect, founder-ledNow to 2027
United KingdomQueen's Belfast support letter and named pilot partner; GPhC frameworkDirect with academic championNow to 2027
CanadaToronto interview; faster procurement flagged in the feasibility studyDirect, then partner2027 to 2028
AustraliaUNSW named as a pilot partner in the feasibility studyPartner-led2027 to 2028
Netherlands, Belgium, PortugalGroningen and Ghent interviews, Lisbon support letter and case-sharing interestUniversity partner, translated content2028 to 2029

Each market is a content and compliance task rather than an engineering one, so entry is gated on evidence from the preceding phase and costed market by market. Base-case revenue assumes Ireland and the UK only; Canada, Australia and Europe are upside, not forecast.

Validation18 / 29

Early validation from educators and pharmacy operators across seven countries

“Our students are always asking for more opportunities to practice.”
Professor, Ghent University
“If you create a system which generates those cases and they are linked with guidelines, that would be really helpful.”
Professor, University of Groningen
“If anyone can figure out how to help with simulations in pharmacy at a large scale, there’s benefit.”
Associate Dean, University of Toronto
“A super idea… a quick win, a quick show of value.”
Pharmacist and investor, former Think Research board member

Feasibility interviews (May 2025) covered Ireland, the UK, Australia, Canada, the Netherlands, Belgium and Portugal. Support letters are recorded from QUB, RCSI and Lisbon. These are qualitative signals, not purchase commitments; the trial programme is designed to convert them into evidence.

Academic engagement19 / 29

Eight institutions across seven countries, with pilot partners already named

8

Institutions engaged

7

Countries represented

3

Written letters of support

Queen’s University Belfast, RCSI and the University of Lisbon

InstitutionCountryEngagementFocus
Trinity College DublinIrelandHome institution; pre-pilot groupScenario research and Trial 0.5 usability
RCSIIrelandSupport letter; pilot partnerAcademic pilot deployment
Queen’s University BelfastUnited KingdomSupport letter; pilot partnerAcademic pilot deployment
University of LisbonPortugalInterview; support letterCase sharing and adaptive content
Ghent UniversityBelgiumInterviewEducator authoring workload
University of GroningenNetherlandsInterviewGuideline-linked cases
University of TorontoCanadaInterviewAccess to simulation at scale
UNSWAustraliaPilot partner named in the feasibility studyAcademic pilot deployment

Engagement is qualitative at this stage: interviews, written support and named pilot partners. No institution has committed to purchase. The trial programme is designed to convert this into measured and priced evidence.

Trial programme20 / 29

Four staged trials generate the evidence buyers need

TrialWhoWhen (provisional)What it tests
0.5 Pre-pilotSmall TCD group, one clinical areaBefore Christmas 2026 or January 2027Usability, unstructured feedback
1 AcademicEducators and studentsJanuary or February 2027Scenario quality and educator effort
2 Broad academicEducators (Jun to Aug), students (Sep 2027)Summer and September 2027Preparation time, quality, learner experience (Likert scales), willingness to pay
3 RegulateOne organisation, two sites, about 20 participantsFebruary 2027Near-miss capture, LASA usability, fit with existing processes

Dates are indicative pending AI delivery estimates and approvals. No patient names or records are captured; the ethics route is being explored and a data-protection review will determine DPIA requirements.

Milestones21 / 29

June 2026 to September 2027: from trials to first paid conversions

  1. Oct 2026

    Trial scope, AI estimates, evaluation requirements, priority accounts

  2. Nov to Dec 2026

    Approved scenarios, guides, pricing discovery, investor preparation

  3. Dec 2026 to Jan 2027

    Trial 0.5; manufacturer-education decision point (Jan); 3 to 5 Regulate buyer conversations

  4. Jan to Feb 2027

    Trial 1 (academic) and Trial 3 (Regulate)

  5. Q2 2027

    8 to 12 substantive investor conversations

  6. Jun to Aug 2027

    Educator Trial 2; funding discussions; costed business model and go-to-market plan

  7. Aug 2027

    3 to 5 institutions expressing intent to pay

  8. Sep 2027

    Student Trial 2; Q4 contingency for funding close

Targets: documented Regulate buying decision by M12; initial paid conversion by M15.

Costs and economics22 / 29

Development is largely built; the next phase measures production costs and margins

Cost structure being modelled

  • AI generation, AI feedback, storage, review and support per scenario and per site
  • Developer tooling and LLM spend, already tracked by the technical lead
  • Staffing, licences, onboarding, legal and IP, sales
  • Customer success capacity, hired against workload and funding

How margins are protected

  • Reuse of approved scenarios to reduce repeat generation cost
  • Usage limits and package definitions set from measured costs
  • Implementation and optional modules priced separately
  • Project funding separated from company costs in the model
Transparency note: production unit costs and gross margin are not yet established. An 18-month financial model post spin-out, with product-level revenue and delivery cost and cash-flow scenarios including academic conversion after the September 2027 student evaluation, is a committed deliverable by August 2027.
The raise23 / 29

Seeking €900k at Seed

20–30

Target investors identified

8–12

Substantive conversations by Q2 2027

Jun–Aug 2027

Target close window

Contingency: Q4 2027

Investor routes

  • Enterprise Ireland PSSF
  • Mainstream venture capital
  • Spin-out funds (TCD spin-out arrangements being prepared)
  • Specialty VC, for example Wake-Up Capital

Use of funds (indicative)

Product and trials50% · €450k

Trial delivery, engineering capacity, production security and compliance

Go-to-market30% · €270k

Educator and pharmacy sales, customer success, partner channel

IP, legal and contingency20% · €180k

Patent filing, freedom to operate, record acceptance, working capital

Indicative split of the €900k seed, refined through the costed roadmap and runway plan.

Risks24 / 29

Key risks and how we are addressing them

RiskMitigation
A free incumbent (MyDispense) anchors academic price expectationsCompete on authoring and review workflow, educator control and curriculum fit; trials measure time saved; test €89 launch price and free faculty access
Price acceptance at €89 per student and €3,000 per site is untestedAsk every trial completer about budget, authority and timing; test both price points in live conversations; add packages if resistance appears
Slow university procurement (3 to 6 months)Start compliance conversations during trials; target intent to pay by August 2027
Pharmacy buyers distrust AI or resist new toolsHuman approval and traceable sources; Regulate positioned as reporting and governance, not automated checking
RL Datix already serves incident reportingDifferentiate on regulator-aligned workflow fit, usability and combined reporting, governance and learning
AI delivery and cost uncertaintyAI estimates in October; measure production cost per scenario; usage limits
Data protection and statutory record requirementsNo patient names or records in trials; DPIA review; acceptance against regulator electronic-record requirements before CD register deployment
IP and compliance25 / 29

Protecting the scenario engine and building for regulated buyers

Intellectual property

  • Provisional patent to be considered for the AI-generated scenario engine (personalisation, guideline adaptation, feedback)
  • Freedom-to-operate analysis advised before commercial launch; prior art reviewed in medication-safety decision support
  • Core adaptive case logic and scoring treated as trade secrets until patentability is confirmed
  • Spin-out arrangements with TCD being prepared

Governance and compliance

  • Evidence Pack traceability, validation and human approval for every scenario
  • GDPR-aligned design, private evidence storage, per-record audit trails
  • Role-based access and consent-managed benchmarking
  • Legal and regulatory requirements built into production acceptance
Read the evidence and assurance specification
Why invest26 / 29

A software business with two recurring revenue lines and a costed route to first contracts

  • A regulated, quantified need: $42bn annual cost of medication errors and a WHO goal to halve severe avoidable harm
  • Subscription revenue from two buyers on one platform: €89 per student per year and €3,000 per pharmacy site per year
  • Built to travel: shared engine and review workflow, jurisdiction-specific content, and interest already recorded across seven countries
  • Revenue ladders already mapped: €107k to €178k from 3 to 5 schools, €150k from 50 pharmacies, against €42m to €54m academic and €6.0m home-market ceilings
  • De-risked spend: product largely built, four trials to convert interest into contracts, intent to pay by August 2027
AccuRxy
Safe Practice
Appendix27 / 29

Sources and basis of figures

Internal figures come from the AccuRXy Commercial Report (V33), the Educate pricing discussion (October 2026) and the May 2025 feasibility study. Where the earlier study described real-time error detection, this deck follows the later commercial report, which scopes Regulate as reporting and governance. Market-size figures differ by source and definition. Revenue figures are modelled scenarios, not forecasts or commitments.

Appendix28 / 29

Scenario creation: brief, generate, review, publish

Educate · Scenario brief
Clinical areaDepression · BNF chapter 4
Year levelYear 3 · Advanced
SettingCommunity pharmacy
ComplexityInteractions and time pressure
Generate 3 variantsEducator review next
Educate · Generated variant

Patient

Margaret Doyle, 68

4 steps · 6 decisions · 2 drugs

Draft
1

Receive

Patient hands in a repeat prescription

2

Review

Screen for interactions and adherence

3

Prepare

Gather, check and label

4

Counsel

Explain the change and follow-up

Educate · Review and approval
Awaiting academic reviewDraft 1.0

Clinical accuracy

Checked against source

Medicines and doses

Validated

Evidence pack

4 sources linked

Curriculum mapping

Regulator competencies

Reviewer sees every source claim

Interface views from the current build. An educator sets the clinical area, year level, setting and complexity; the platform drafts variants; nothing reaches a student until academic review and approval are recorded.

Appendix29 / 29

Regulate: professional user's dashboard

regulate.accurxy.com/safety-dashboard
RxAccuRxy Safety
Safety dashboard
Report incident
My reports
Action plans
Error analytics
SOP library
Inspection preparation
Team and roles
Settings

Safety dashboard

Ballymount Pharmacy · reporting period: this quarter

SO

24

Reports this quarter

7

Open actions

1

Overdue

86%

Closed on time

RefTypeStageStatus
INC-0148Near missDispensingOpen
INC-0147Dispensing errorDispensingAction
INC-0146LASA selectionCounsellingClosed
INC-0145DocumentationSupplyClosed
Good catch Export inspection evidence

Layout reconstructed from the live build at accurxy2.redcert.com, whose public entry point is the sign-in screen. Menu: safety dashboard, report incident, my reports, action plans, error analytics, SOP library, inspection preparation, team and roles, settings. On-screen names, references and figures are illustrative, not trial data.

01 / 29